Page 15 - Noble-Virtual-Healthcare-2024

Anavex Life Sciences Corp.

SELECTED FINANCIAL ITEMS AVXL

(in millions of USD)
CQ1 '23 CQ2 '23 CQ3 '23 CQ4 '23 LTM
Income Statement Key Items
Total Revenue NA NA NA NA 0.00
Gross Profit NA NA NA NA 0.00
Gross Margin NM NM NM NM NM
EBIT (13.44) (12.97) (11.98) (10.70) (49.09)
EBIT Margin NM NM NM NM NM
Net Income to Common Shareholders (13.11) (11.28) (10.15) (8.62) (43.16)
Net Margin NM NM NM NM NM

Balance Sheet Key Items
Total Assets 159.19 157.81 154.39 148.07 148.07
Cash & Short Term Investments 153.47 154.82 151.02 143.77 143.77
% of Assets 96% 98% 98% 97% 97%
Current Assets -Total 159.19 157.81 154.39 148.07 148.07
% of Assets 100% 100% 100% 100% 100%
Total Liabilities 14.02 11.06 12.53 12.50 12.50
% of Assets 9% 7% 8% 8% 8%
Current Liabilities - Total 14.02 11.06 12.53 12.50 12.50
% of Assets 9% 7% 8% 8% 8%
Long Term Debt NA NA NA NA NA
% of Assets NM NM NM NM NM
Total Equity 145.17 146.75 141.85 135.58 135.58
% of Assets 91% 93% 92% 92% 92%

Cash Flow Statement Key Items
Net Cash Flow - Operating Activities (8.49) (7.65) (5.85) (7.32) (29.31)
Net Cash Flow - Investing NA NA NA NA 0.00
Net Cash Flow - Financing 18.33 9.00 2.06 0.06 29.45

Source: Capital IQ

PRICE / VOLUME

Source: Channelchek/QuoteMedia

Noble Capital Markets' Nineteenth Annual Small & Microcap Investor Conference